Table 2.
Demographic and clinical characteristics of the analytical cohort by histology
| Baseline characteristics | Histology | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall | Non-squamousa | Squamous | Not otherwise specified | |||||
| n | %b | n | %b | n | %b | n | %b | |
| 81,628 | 100% | 46,670 | 57% | 21,540 | 26% | 13,418 | 16% | |
| Year of diagnosis | ||||||||
| 2008 | 2535 | 3.1% | 1125 | 2.4% | 613 | 2.8% | 797 | 5.9% |
| 2009 | 3781 | 4.6% | 1809 | 3.9% | 998 | 4.6% | 974 | 7.3% |
| 2010 | 5186 | 6.4% | 2566 | 5.5% | 1362 | 6.3% | 1258 | 9.4% |
| 2011 | 6575 | 8.1% | 3455 | 7.4% | 1533 | 7.1% | 1587 | 11.8% |
| 2012 | 8037 | 9.8% | 4334 | 9.3% | 1966 | 9.1% | 1737 | 12.9% |
| 2013 | 9423 | 11.5% | 5275 | 11.3% | 2483 | 11.5% | 1665 | 12.4% |
| 2014 | 10254 | 12.6% | 5909 | 12.7% | 2674 | 12.4% | 1671 | 12.5% |
| 2015 | 10077 | 12.3% | 6072 | 13.0% | 2740 | 12.7% | 1265 | 9.4% |
| 2016 | 9870 | 12.1% | 6097 | 13.1% | 2696 | 12.5% | 1077 | 8.0% |
| 2017 | 8948 | 11.0% | 5590 | 12.0% | 2523 | 11.7% | 835 | 6.2% |
| 2018 | 6942 | 8.5% | 4438 | 9.5% | 1952 | 9.1% | 552 | 4.1% |
| Gender | ||||||||
| Male | 39987 | 49.0% | 20762 | 44.5% | 12722 | 59.1% | 6503 | 48.5% |
| Female | 41599 | 51.0% | 25885 | 55.5% | 8809 | 40.9% | 6905 | 51.5% |
| Unknown | 42 | 0.1% | 23 | 0.0% | 9 | 0.0% | 10 | 0.1% |
| Region | ||||||||
| Midwest | 38317 | 46.9% | 21450 | 46.0% | 10708 | 49.7% | 6159 | 45.9% |
| South | 23171 | 28.4% | 13070 | 28.0% | 6445 | 29.9% | 3656 | 27.2% |
| West | 7559 | 9.3% | 4671 | 10.0% | 1828 | 8.5% | 1060 | 7.9% |
| Northeast | 10380 | 12.7% | 6263 | 13.4% | 1974 | 9.2% | 2143 | 16.0% |
| Other/Unknown | 2201 | 2.7% | 1216 | 2.6% | 585 | 2.7% | 400 | 3.0% |
| Race | ||||||||
| Caucasian | 69138 | 84.7% | 38996 | 83.6% | 18659 | 86.6% | 11483 | 85.6% |
| African American | 7270 | 8.9% | 4385 | 9.4% | 1795 | 8.3% | 1090 | 8.1% |
| Asian | 1164 | 1.4% | 869 | 1.9% | 137 | 0.6% | 158 | 1.2% |
| Other/unknown | 4056 | 5.0% | 2420 | 5.2% | 949 | 4.4% | 687 | 5.1% |
| Ethnicity | ||||||||
| Non-Hispanic | 73931 | 90.6% | 42329 | 90.7% | 19718 | 91.5% | 11884 | 88.6% |
| Hispanic | 1507 | 1.8% | 970 | 2.1% | 320 | 1.5% | 217 | 1.6% |
| Unknown | 6190 | 7.6% | 3371 | 7.2% | 1502 | 7.0% | 1317 | 9.8% |
| Age at diagnosis (in years) | ||||||||
| Mean (SD) | 69.1 (10.12) | 68.5 (10.44) | 70.3 (9.32) | 69.4 (10.02) | ||||
| Median (IQR) | 70 (62–77) | 69 (61–77) | 71 (64–78) | 70 (63–77) | ||||
| Min–Max | (18–89) | (18–89) | (23–89) | (21–89) | ||||
| ≤ 34 | 117 | 0.1% | 89 | 0.2% | 11 | 0.1% | 17 | 0.1% |
| 35–44 | 835 | 1.0% | 614 | 1.3% | 92 | 0.4% | 129 | 1.0% |
| 45–54 | 6161 | 7.5% | 4004 | 8.6% | 1151 | 5.3% | 1006 | 7.5% |
| 55–64 | 18797 | 23.0% | 11475 | 24.6% | 4423 | 20.5% | 2899 | 21.6% |
| 65+ | 55718 | 68.3% | 30488 | 65.3% | 15863 | 73.6% | 9367 | 69.8% |
| ECOG score | ||||||||
| Index ± 30 days | ||||||||
| 0 | 3054 | 28.8% | 2201 | 31.5% | 701 | 23.5% | 152 | 23.9% |
| 1 | 4372 | 41.2% | 2866 | 41.0% | 1261 | 42.3% | 245 | 38.5% |
| 2 | 1909 | 18.0% | 1143 | 16.3% | 633 | 21.3% | 133 | 20.9% |
| 3 | 1010 | 9.5% | 630 | 9.0% | 301 | 10.1% | 79 | 12.4% |
| 4 | 262 | 2.5% | 155 | 2.2% | 80 | 2.7% | 27 | 4.2% |
| 5 | 4 | 0.0% | 2 | 0.0% | 2 | 0.1% | 0 | 0.0% |
| Missing | 71017 | 39673 | – | 18562 | – | 12782 | - | |
| Stage | ||||||||
| Index through follow-up (localized unknown) ± 30 days (locally advanced metastatic) | ||||||||
| Localized (stage ≤ 3a) | 20425 | 59.4% | 13103 | 54.0% | 6807 | 70.6% | 515 | 100.0% |
| Locally advanced/metastasis (≥ 3b) | 13973 | 40.6% | 11142 | 46.0% | 2831 | 29.4% | 0 | 0.0% |
| Unknown | 24516 | – | 11395 | – | 6270 | – | 6851 | – |
| Missing | 22714 | – | 11030 | – | 5632 | – | 6052 | – |
| Cytogenetics | ||||||||
| Any time | ||||||||
| EGFR-positivec | 9267 | 38.3% | 8208 | 44.6% | 704 | 15.6% | 355 | 27.2% |
| EGFR-negative | 5575 | 23.0% | 4303 | 23.4% | 988 | 22.0% | 284 | 21.7% |
| PD-L1–positive | 1933 | 8.0% | 1140 | 6.2% | 730 | 16.2% | 63 | 4.8% |
| PD-L1–negative | 487 | 2.0% | 354 | 1.9% | 122 | 2.7% | 11 | 0.8% |
| Both | 448 | 1.8% | 399 | 2.2% | 38 | 0.8% | 11 | 0.8% |
| Other | 6510 | 26.9% | 4010 | 21.8% | 1917 | 42.6% | 583 | 44.6% |
| Missing | 57408 | – | 28256 | – | 17041 | – | 12111 | - |
| Charlson comorbidityd | n = 81778 | n = 38455 | n = 18004 | n = 6715 | ||||
| Mean (SD) | 1.8 (2.56) | 2 (2.74) | 1.7 (2.34) | 1.4 (2.22) | ||||
| Median | 1 (0–3) | 1 (0–3) | 1 (0–2) | 0 (0–2) | ||||
| Min–Max | (0–16) | (0–15) | (0–16) | (0–14) | ||||
ECOG Eastern Cooperative Oncology Group; EGFR epidermal growth factor receptor; PD-L1 programmed death-ligand 1; IQR interquartile range; SD standard deviation
aPatients with squamous cell carcinoma were compared against patients with non-squamous cell carcinoma only; non-squamous NSCLC includes adenocarcinoma and large cell lung cancer; patients with unknown histology were excluded from this analysis
bPercentages are based on non-missing values in respective cohort
cA patient was EGFR-mutant if identified as EGFR-positive from the SDS data set or had received osimertinib, erlotinib, afatinib, gefitinib or dacomitinib (monotherapy or in combination with chemotherapy drugs) in LOT1. Chemotherapy drugs: Carboplatin, cisplatin, docetaxel, gemcitabine, nab-paclitaxel, paclitaxel, pemetrexed, or vinorelbine
dComorbidities identified during the 180-day pre-index period